^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    F007 (rituximab biosimilar)

    i
    Other names: F007, H02
    Associations

    News

    Trials
    Company:
    Lunan Pharma
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost3years
    A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL (clinicaltrials.gov)
    P2, N=62, Not yet recruiting, Shandong New Time Pharmaceutical Co., LTD
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    F007 (rituximab biosimilar) • rulonilimab (F520)